The research, carried out by Federico Lasagni, Robab Ezazi, Marilisa Giavalisco, Stefano Cassanelli, Alessandro Ulrici, Maria Gullo and Teresa Zotta, was funded by the PRIN 2022 project SynBioCell, which targets sustainable bacterial cellulose production for food and health applications, and was supported by the Italian national node MIRRI-IT of the European Research Infrastructure MIRRI-ERIC. The work addresses a well-recognized bottleneck. Acetic acid bacteria, or AAB, are acknowledged as high producers of bacterial cellulose, but the amount they synthesize fluctuates considerably depending on the strain and on a range of environmental and nutritional factors. That variability has practical consequences: any strategy that makes cellulose production more reliable and more productive is of immediate relevance to bioprocess developers.

Instead of relying on trial and error, the team turned to design of experiments, a chemometric framework that allows many variables to be screened and optimized with a statistically controlled number of trials. Their strategy unfolded in two sequential stages. First, two Plackett-Burman designs, screening designs prized for their efficiency in identifying which factors among many actually matter, were used to construct and screen synthetic microbial communities, or SynComs. These communities were assembled from three functional groups: acetic acid bacteria, lactic acid bacteria, and yeasts. In total, twelve different SynComs were built and tested, spanning combinations of AAB alone, AAB with lactic acid bacteria, AAB with yeasts, and communities containing all three groups.

The logic behind mixing species is ecological as much as biochemical. In natural fermentation ecosystems, such as those governing vinegar and kombucha production, acetic acid bacteria rarely act alone. Lactic acid bacteria and yeasts can alter the pH, consume or release metabolites, and create conditions that either help or hinder cellulose-producing strains. By treating community composition itself as an experimental variable, the researchers could ask a question that monoculture studies cannot address: does the identity of the neighbors matter as much as the identity of the producer? The Plackett-Burman screening answered emphatically that it does. The composition of the SynComs significantly affected bacterial cellulose production, and several communities outperformed some of the acetic acid bacteria monocultures tested alongside them.

Having narrowed the field, the researchers moved to the second stage: a circumscribed central composite design, or CCC, a response-surface methodology that fits a mathematical model describing how the response, in this case cellulose titre, changes across a continuum of culture conditions. This allowed the team not merely to pick the best condition among those tested, but to predict where the true optimum lies, including at combinations of factor levels never directly run in the experiment. The factors optimized included glucose concentration, temperature, and cultivation time, three of the most influential levers in any microbial fermentation process.

The outcome was a consortium containing both lactic acid bacteria and yeasts as helper strains alongside the cellulose producer. Under the optimized conditions, 50 grams per liter of glucose, a temperature of 32 degrees Celsius, and a cultivation period of seven days, this SynCom reached a bacterial cellulose titre of 10.40 plus or minus 0.40 grams per liter. For comparison, the best performer among the acetic acid bacteria monocultures, a strain carrying a deletion in the gdh gene, designated the AAB monoculture Δgdh K2G30, produced 10.79 plus or minus 0.36 grams per liter. The difference between the engineered community and the single best strain was within experimental uncertainty, meaning the consortium effectively matched the champion monoculture.

Just as important for process development, the measured production level agreed closely with the model’s forecast. The circumscribed central composite design’s regression model predicted a cellulose titre of 10.53 grams per liter under the same conditions, a figure the experimental result confirmed within its error range. That agreement matters because it validates the entire statistical pipeline: if the response-surface model had diverged sharply from reality, the optimization would have been little more than an elaborate curve fit. Instead, the researchers can now use the model to explore neighboring conditions and to reason about scale-up with quantitative confidence.

The study’s authors are careful about what remains unknown. Although the community-level results are striking, the roles and interactions among the individual community members have not yet been resolved. Whether the lactic acid bacteria and yeasts are supplying growth factors, buffering acidity, scavenging inhibitory byproducts, or reshaping the metabolic flux of the cellulose producer is a question for future metabolic and population dynamics analyses. Such work, tracking which species persist, in what proportions, and what they exchange over the course of a seven-day fermentation, will be essential before synthetic communities can be deployed reliably at industrial scale, where community stability under continuous operation becomes a critical concern.

Even so, the conceptual advance is considerable. Bacterial cellulose is chemically identical to plant cellulose but free of lignin and hemicellulose, which makes it attractive for wound dressings, tissue engineering scaffolds, and novel food textures. Production costs, however, have limited its adoption, and much of the field has focused on genetic engineering of producer strains such as Komagataeibacter xylinus. This study offers a complementary route: rather than modifying the producer’s genome, modify its social environment. The finding that several SynComs outperformed some acetic acid bacteria monocultures suggests that helper organisms can unlock productivity that a single strain cannot reach on its own, and that this effect can be captured systematically rather than stumbled upon.

The methodological lesson may prove as influential as the biological one. Sequential design of experiments, moving from Plackett-Burman screening to central composite response-surface optimization, gave the researchers a disciplined path from twelve candidate communities to one optimized recipe and one validated set of culture conditions, all with a manageable number of experiments. As synthetic microbial communities attract growing interest across biotechnology, from waste valorization to probiotic formulation, the ability to assemble and tune them statistically, rather than intuitively, could become standard practice. For bacterial cellulose specifically, the results point toward more versatile fermentation processes in which consortia, not lone strains, do the manufacturing, a perspective the authors present as a new direction for future development in food and biomedical applications.

Subject of Research: Design-of-experiments-guided assembly of synthetic microbial communities to optimize bacterial cellulose production

Article Title: DOE-guided assembly and optimization of Synthetic Microbial Communities for bacterial cellulose production

Article References: Lasagni, F., Ezazi, R., Giavalisco, M., Cassanelli, S., Ulrici, A., Gullo, M., & Zotta, T. (2026). DOE-guided assembly and optimization of Synthetic Microbial Communities for bacterial cellulose production. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14059-7

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14059-7

Keywords: bacterial cellulose, synthetic microbial communities, acetic acid bacteria, lactic acid bacteria, yeasts, design of experiments, Plackett-Burman design, central composite design, Komagataeibacter xylinus, fermentation optimization, biopolymer, industrial microbiology

The drive to replace synthetic dyes has never been more urgent. Common artificial colorants such as Allura Red, Tartrazine, Sunset Yellow, and Ponceau have been linked in various studies to oxidative damage in multiple organs, systemic inflammation, immune suppression, reduced male fertility, and allergic reactions affecting the skin, respiratory tract, and digestive system, particularly in children. Their environmental footprint is equally troubling: the same chemical stability that makes synthetic dyes attractive to manufacturers makes them poorly biodegradable, allowing them to persist and accumulate in water, soil, plants, and animals, with transformation products that may be toxic or potentially carcinogenic. Natural pigments from microalgae, lichens, plants, and bacteria have emerged as safer alternatives, and bacterial pigments in particular combine renewability, biocompatibility, and documented bioactivities ranging from antioxidant to anti-inflammatory and antimicrobial effects.

Indigoidine has long intrigued scientists because of its striking blue hue and its pharmacological promise, but producing it at industrially meaningful yields has been a persistent bottleneck. The new work began with a systematic comparison of culture media, screening Nutrient Broth, Tryptic Soy Broth, Peptone Glycerol Broth, and Luria-Bertani (LB) medium. Although Peptone Glycerol Broth supported the fastest bacterial growth, standard LB medium proved the most productive for pigment synthesis, yielding 75.8 milligrams of indigoidine per liter per 24 hours. The researchers then applied a two-stage statistical optimization strategy, first using a Plackett-Burman mixture design to identify the most influential nutritional and physicochemical variables, and then refining the three dominant factors with a central composite design implemented in Minitab software.

The results of that optimization were dramatic. Raising tryptone to 1.52 percent and yeast extract to 0.81 percent, introducing glucose at about 1 percent along with l-glutamine, magnesium sulfate, and potassium phosphate, and adjusting the culture to pH 7.8, 29 degrees Celsius, and 200 rpm agitation lifted indigoidine output to 177.4 milligrams per liter per 24 hours, a 2.34-fold increase over the standard medium. The response surface model predicted a maximum near 180 milligrams per liter, and the experimental value landed almost exactly on target, validating the statistical approach. The authors attribute the gains to a richer supply of amino acid and peptide precursors, improved ATP and cofactor availability, better oxygen transfer from increased agitation, and the metabolic support provided by magnesium and phosphate ions. Molecular oxygen is especially critical because it reoxidizes flavin mononucleotide during the enzymatic step catalyzed by the pigment-synthesizing enzyme BpsA.

Purification and characterization confirmed the quality of the product. Following ultrasonic disruption of the bacterial cells and a series of centrifugation and filtration steps, the pigment was recovered as a lyophilized powder with a purity of 92.3 percent, verified by LC-MS and by UV-visible spectroscopy showing the characteristic absorbance maximum at 612 nanometers. Stability testing then mapped how the pigment behaves under food-processing conditions. Indigoidine was most stable near neutral pH, with a half-life of about 150 hours at pH 7.8, but degraded rapidly at extremes, dropping to half-lives of just 3 hours at pH 1 and 10 hours at pH 12. Temperature told a similar story: the pigment endured for 240 hours at 4 degrees Celsius but lost half its content within 2 hours at 100 degrees Celsius. Darkness preserved it best, with a 220-hour half-life, while ultraviolet exposure cut that figure to 20 hours. These findings suggest that indigoidine is well suited to neutral-pH, refrigerated, light-protected applications.

Safety and bioavailability assessments added further credibility to the pigment’s industrial prospects. In a hemolysis assay using freshly isolated human erythrocytes, indigoidine caused less than 2 percent hemolysis at concentrations between 0.5 and 10 micrograms per milliliter, and even at the highest tested dose of 50 micrograms per milliliter hemolysis reached only 5.29 percent, within the generally accepted nontoxic threshold. A membrane distribution experiment showed that the pigment readily penetrates human cell membranes: at low concentrations more than 87 percent of the indigoidine was found inside the erythrocytes, indicating efficient cellular uptake, a property that could allow the molecule to reach intracellular targets in food and pharmaceutical contexts.

The most striking results, however, concerned metabolism. In what the study describes as a first, indigoidine was tested against key enzymes implicated in obesity and diabetes. The pigment inhibited alpha-amylase, the enzyme that breaks down starch and drives postprandial glucose spikes, with an IC50 of 0.69 micrograms per milliliter, close to the 0.36 micrograms per milliliter of the clinical drug acarbose. Molecular docking supported the finding, with a binding energy of minus 7.4 kilocalories per mole versus minus 7.7 for acarbose, and hydrogen bonds to ASP197, ASP300, and GLN63 plus pi-pi interactions with TRP59 stabilizing the complex. Against pancreatic lipase, the fat-digesting enzyme targeted by the anti-obesity drug orlistat, indigoidine actually outperformed the reference compound, achieving an IC50 of 0.37 micrograms per milliliter compared with 0.62 for orlistat, and a stronger docking score of minus 8.1 versus minus 6.9 kilocalories per mole.

Beyond blocking digestion, indigoidine activated the two master switches of cellular energy handling. AMPK, the cellular fuel gauge and a major therapeutic target for diabetes and insulin resistance, was stimulated in a dose-dependent manner up to 65.1 percent activation, with an EC50 of 1.36 micrograms per milliliter, near the 0.98 micrograms per milliliter of the reference activator A-769662. AKT, or protein kinase B, the linchpin of insulin signaling, glucose transport, and glycogen synthesis, was activated up to 65.6 percent with an EC50 of 4.59 micrograms per milliliter and a docking affinity almost identical to that of the standard activator SC79. To test these effects in a living, highly metabolic human cell system, the researchers exposed spermatozoa to the pigment. Glucose consumption rose to 133.4 percent of control at 20 micrograms per milliliter, AMPK activity peaked at 128.9 percent, and AKT activity reached 121.4 percent, all while showing less toxicity at high doses than either A-769662 or SC79, which suppressed metabolism sharply at elevated concentrations.

The convergence of enzyme inhibition, signaling activation, membrane penetration, and low hemotoxicity positions indigoidine as a rare multitarget natural compound, one that could serve simultaneously as a food colorant and a functional bioactive ingredient. The authors caution, however, that several hurdles remain before the pigment can move toward therapeutic use. In vivo studies are needed to confirm the metabolic effects observed in vitro, comprehensive toxicity and safety evaluations must be completed, pharmacokinetics and bioavailability in the body remain uncharacterized, and the precise molecular mechanisms of AMPK and AKT modulation require deeper investigation. Formulation optimization and scale-up of production will also be essential for any commercial application.

Even with those caveats, the study marks a significant advance on two fronts at once. It demonstrates that rational, statistics-guided fermentation can more than double the yield of a bacterial pigment without genetic manipulation of the production strain, and it reveals that the same molecule coloring our foods may also help regulate the digestive enzymes and metabolic pathways implicated in two of the world’s most widespread chronic diseases. As pressure mounts to phase out synthetic dyes and to find gentler, multifunctional alternatives, the deep blue chemistry of indigoidine may prove to be one of microbiology’s most colorful contributions to human health.

Subject of Research: Sustainable fermentation overproduction of the bacterial pigment indigoidine and its inhibitory and activating effects on enzymes involved in obesity, diabetes, and insulin signaling

Article Title: Sustainable Overproduction of the Bacterial Pigment Indigoidine as a Natural Colorant: Stability Evaluation, Inhibition of Obesity‐Diabetes‐Related Digestive Enzymes, and Activation of AMPK–AKT

Article References: Sustainable Overproduction of the Bacterial Pigment Indigoidine as a Natural Colorant: Stability Evaluation, Inhibition of Obesity‐Diabetes‐Related Digestive Enzymes, and Activation of AMPK–AKT. (n.d.). https://doi.org/10.1002/mbo3.70429

Image Credits: AI Generated

DOI: 10.1002/mbo3.70429

Keywords: indigoidine, bacterial pigment, natural colorant, fermentation optimization, alpha-amylase inhibition, pancreatic lipase, AMPK activation, AKT signaling, type 2 diabetes, obesity, Escherichia coli, food safety

L-glutamic acid is far more than a flavoring agent. It is one of the most abundant amino acids in nature, a central hub of nitrogen metabolism in living cells, and the principal excitatory neurotransmitter in the mammalian nervous system. Industrially, it is produced almost exclusively through microbial fermentation, with the bacterium Corynebacterium glutamicum serving as the dominant workhorse thanks to decades of metabolic engineering. Yet the global appetite for glutamate, driven by its use as a flavor enhancer and its expanding role in food biotechnology, has pushed researchers to look for alternative microbial producers. Lactic acid bacteria are particularly attractive candidates because of their long history of safe use in food, their metabolic versatility, and their regulatory standing as Generally Recognized as Safe in the United States and as holding Qualified Presumption of Safety status in the European Union. The biosynthesis of glutamate in these bacteria is closely tied to the enzyme glutamate dehydrogenase, which catalyzes the amination of alpha-ketoglutarate, and the presence of the gdh gene in many lactic acid bacteria confirms their genetic capacity for the task.

The Brazilian team began with a simple but ambitious question: how many of the lactic acid bacteria in their culture collection could actually make glutamic acid? The 142 isolates, drawn from species including Levilactobacillus brevis, Lacticaseibacillus casei, L. paracasei, Lactiplantibacillus plantarum, and L. fermentum, were grown under microaerobic conditions and tested first by thin-layer chromatography, which revealed that every single isolate produced detectable glutamate. Quantitative screening with a ninhydrin colorimetric assay showed average production of 20.0 millimolar, with values ranging from 10.60 to 33.78 millimolar. Using a selection threshold of 27.19 millimolar, the researchers narrowed the field to 17 high-producing strains, eight of which came from traditional indigenous fermented beverages and nine from other fermented substrates such as fresh pork sausage, cocoa, apple kefir, apple, and pulped coffee.

Precise quantification by high-performance liquid chromatography exposed striking variability among the selected strains, confirming that glutamate production is a highly strain-dependent trait rather than a species-wide characteristic. Extracellular concentrations ranged from 2.42 to 31.97 millimolar, while intracellular accumulation varied from 1.26 to 44.83 millimolar. The two standouts were both L. fermentum strains isolated from Yakupa: CCMA 0209 accumulated the highest intracellular glutamate at 44.83 millimolar, while CCMA 0205 secreted the most extracellular glutamate at 31.97 millimolar. This split between accumulation inside the cell and secretion into the surrounding medium hints that glutamate production and export may be independently regulated processes, a distinction well documented in Corynebacterium glutamicum, where mechanosensitive channels such as MscCG govern glutamate release. Whether similar export mechanisms operate in lactic acid bacteria remains an open question for future research.

With four top producers in hand, the team turned to statistical optimization using a Central Composite Rotational Design, a response surface methodology that evaluates pH, temperature, and incubation time at five coded levels to map how these variables jointly influence production. Only L. fermentum CCMA 0205 yielded a statistically significant predictive model for extracellular glutamate, with a coefficient of determination of 0.83 and a non-significant lack-of-fit test, meaning the fitted equation reliably described the experimental data. Temperature and incubation time emerged as the dominant factors, while pH showed no significant effect within the studied range. Counterintuitively, production was favored at the lower end of the temperature scale and at shorter incubation times, with the highest observed value in the design runs, 4.694 millimolar, obtained at pH 5.5, 30 degrees Celsius, and 48 hours. Higher temperatures and prolonged fermentation reduced yields, possibly through nutrient depletion, accumulation of inhibitory metabolites, or degradation of the amino acid itself.

The researchers are careful to note an important caveat: the 31.97 millimolar figure from the initial screening reflects a seven-day incubation of 168 hours, whereas the optimization design was capped at 112 hours for experimental feasibility. Because the known higher-producing condition lies outside the investigated time domain, the model cannot establish an overall production optimum, and the team recommends that future studies explore longer fermentation times. Numerical optimization within the evaluated design space nevertheless identified a predicted extracellular optimum of 3.86 millimolar at pH 5.5, 30 degrees Celsius, and 48 hours, with a desirability of 0.813. These predictions, the authors stress, require experimental validation before any industrial application.

Intracellular accumulation told a different story. For CCMA 0205, none of the linear effects of pH, temperature, or time reached statistical significance on their own; only the quadratic components mattered, indicating a nonlinear response governed by the combined effects of all three variables. The model explained 84.6 percent of the variability, and numerical optimization pointed to a well-defined maximum of 4.13 millimolar at pH 4.69, 35.3 degrees Celsius, and 72.7 hours. The distinct optima for extracellular and intracellular production suggest that the two processes respond to different physiological signals, reflecting the balance between glutamate biosynthesis, cellular demand, and export. Notably, another strain, L. plantarum SAU 245, reached an intracellular concentration of 10.43 millimolar under specific conditions, but without a significant predictive model its response was too inconsistent to support process development.

Beyond its glutamate output, CCMA 0205 impressed the team with its probiotic-related profile. None of the four selected strains showed hemolytic or DNase activity, two traits commonly associated with bacterial virulence, providing an early safety signal. All strains exhibited high cell surface hydrophobicity exceeding 89 percent, comparable to or higher than values reported for recognized probiotic strains such as Lactobacillus rhamnosus GG and L. plantarum 299v. CCMA 0205 went further, achieving coaggregation rates of 65.71 percent with enteropathogenic Escherichia coli and 65.39 percent with Salmonella enterica serovar Enteritidis, significantly outperforming the other isolates. High hydrophobicity and coaggregation are indirect indicators of an ability to adhere to the intestinal mucosa and to exclude enteric pathogens through competitive interactions, though the authors emphasize that in vitro assays alone do not establish probiotic status and that epithelial adhesion models and in vivo studies will be needed.

Perhaps the most instructive lesson of the study concerns what makes a strain industrially valuable. Several isolates occasionally outperformed CCMA 0205 in individual experimental runs, but the absence of statistically robust predictive models for those strains limits their usefulness, because reproducibility and controllability are paramount in fermentation scale-up. CCMA 0205’s stable, predictable metabolic response, even when its absolute values were not always the highest, is precisely what process engineers need to design rational fermentation strategies. The finding also reinforces a growing appreciation that traditional fermented foods, where microbial communities have adapted to highly competitive ecological niches over generations, are reservoirs of metabolic capabilities that industrial starter cultures often lack.

The convergence of efficient glutamate secretion, predictable fermentation behavior, and favorable surface properties positions L. fermentum CCMA 0205 as a candidate for multifunctional starter cultures that could simultaneously enhance the nutritional, sensory, and functional quality of fermented foods. The research team, supported by Brazil’s National Council for Scientific and Technological Development and the Minas Gerais Research Foundation, plans next to evaluate the strain at pilot scale and to investigate the molecular mechanisms underlying glutamate biosynthesis and secretion in lactic acid bacteria. If those efforts succeed, the umami-enhancing microbe of the future may trace its origins not to an industrial fermenter, but to a centuries-old indigenous beverage from the Brazilian interior.

Subject of Research: L-glutamic acid production and probiotic characterization of lactic acid bacteria isolated from Brazilian fermented foods

Article Title: L-Glutamic acid production by lactic acid bacteria from Brazilian fermented foods: screening, optimization, and probiotic-related properties of Limosilactobacillus fermentum CCMA 0205

Article References: de Lara de Souza, J. G., de Souza, A. C., de Castro, A. T., de Menezes Daloso, D., Schwan, R. F., & Dias, D. R. (2026). L-Glutamic acid production by lactic acid bacteria from Brazilian fermented foods: screening, optimization, and probiotic-related properties of Limosilactobacillus fermentum CCMA 0205. International Microbiology. https://doi.org/10.1007/s10123-026-00905-1

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00905-1

Keywords: L-glutamic acid, lactic acid bacteria, Limosilactobacillus fermentum, Yakupa, fermented foods, umami, probiotics, response surface methodology, fermentation optimization, HPLC, indigenous beverages, food biotechnology

The team, led by Dounya Achwak Chemmam of the University of Jijel, grew the fungus for twenty-one days and extracted its metabolic products with ethyl acetate, a solvent chosen for its ability to pull moderately polar organic molecules out of fungal biomass. When that crude extract was tested against a panel of pathogenic microorganisms, the numbers were striking. The minimum inhibitory concentration, or MIC, the lowest dose that halts visible microbial growth, was just 7.5 micrograms per milliliter against Staphylococcus aureus ATCC 43300 and 15 micrograms per milliliter against Bacillus cereus ATCC 14579. For a raw, unfractionated extract, those values are competitive with many purified natural-product antibiotics and suggest that the active constituents are present at meaningful levels rather than as trace contaminants.

Antibacterial potency was only the beginning. The same extract showed an IC50 of 33.27 micrograms per milliliter in an anti-inflammatory assay, meaning that half of the measured inflammatory activity was suppressed at that concentration. In an antidiabetic screen targeting enzymes that break down dietary sugars, the extract achieved an IC50 of just 3.32 micrograms per milliliter, an exceptionally low figure that points to strong inhibition of carbohydrate-hydrolyzing enzymes. Inhibiting these enzymes is a validated strategy for managing blood glucose spikes after meals, and fungal metabolites have increasingly been flagged as alternatives to synthetic drugs such as acarbose. Finally, the extract exhibited antiproliferative activity with an IC50 of 124.16 micrograms per milliliter against the tested cell line, a more modest but still noteworthy effect that rounds out the pharmacological profile.

Because the activity of a fungal extract depends heavily on how the organism is grown, the researchers next turned to fermentation optimization using the one-factor-at-a-time method, systematically varying culture conditions to find the settings that maximize antimicrobial output. The tuned conditions produced dramatic gains. Against Escherichia coli, the optimized cultures generated a zone of inhibition of 19 millimeters; against Klebsiella pneumoniae, 23 millimeters; and against Bacillus cereus, an impressive 34 millimeters. That last figure is particularly significant because Bacillus cereus is a spore-forming foodborne pathogen, and activity of that magnitude against it suggests the extract could have applications well beyond the clinic, including food preservation and agricultural biocontrol.

What exactly is inside the extract? To answer that, the team deployed two complementary analytical techniques. Gas chromatography coupled to mass spectrometry, or GC-MS, separates volatile and semi-volatile compounds and fragments them into characteristic mass fingerprints that can be matched against spectral libraries. High-performance liquid chromatography, or HPLC, handles compounds that are less volatile or more thermally fragile. Together, the two methods revealed fourteen distinct metabolites produced by PB1, a chemically diverse roster that includes small organic acids, sugars, and more exotic structures.

The identified compounds read like a short course in fungal chemistry. Among them are 3-methylbutanoic acid and propanoic acid, short-chain fatty acids with documented antimicrobial effects against oral and other pathogens; ethylene glycol and 2,3-butanediol, small alcohols whose antibacterial properties have only recently attracted attention; and lactic acid alongside 2,3-dihydroxy-3-methylpropanoic acid, both hydroxy acids that can disrupt microbial membranes. The list also contains phosphorylated and siloxane-containing species, the sugars D-fructofuranose pentakis and D-psicofuranose pentakis, the plant-like glycoside erigeside B, D-galactonic acid, a bufadienolide-type steroid called bufa-20,22-dienolide, and the nucleoside uridine, a molecule that has inspired synthetic small-molecule inhibitors in medicinal chemistry.

No single one of these compounds may account for the full spectrum of activity on its own. More likely, the extract works through additive or synergistic interactions, a common feature of crude natural-product mixtures that pharmaceutical chemists are only beginning to exploit systematically. The presence of short-chain fatty acids could underpin much of the antibacterial effect, while the glycosides and the bufadienolide are plausible contributors to the cytotoxic and enzyme-inhibiting activities. Disentangling those contributions, through bioassay-guided fractionation, will be the essential next step before any clinical relevance can be claimed.

Context matters for this discovery. Penicillium citrinum is a species with a storied double reputation. On one hand, it is the original source of mevastatin, the first statin cholesterol-lowering drug, and its relatives have given medicine compounds ranging from antibiotics to immunosuppressants. On the other hand, the species is known for citrinin, a mycotoxin that contaminates grains and other foods, which means any future development of PB1-derived products would need careful toxicological scrutiny. The current study did not report citrinin among the fourteen detected metabolites, but the genus-level history is a reminder that bioactivity and toxicity often travel together in fungal chemistry and must be evaluated in parallel.

The choice of source organism is also part of the story. Almonds are a nutritionally celebrated food, and the fungi that colonize them occupy a niche that sits at the intersection of food safety and chemical innovation. Isolating a strain from a common pantry item and finding MIC values in the single-digit microgram range underscores how much pharmacological potential remains locked in ordinary environments. The Algerian team has previously described bioactive Penicillium strains from electronic waste and sea sand, and this new work extends that survey into the food chain, reinforcing the idea that productive fungi are distributed across wildly different habitats.

For now, the findings remain at the level of in vitro biochemistry: enzyme assays, microbial cultures, and cell lines, not patients. Translating a crude extract into a drug candidate typically requires years of fractionation, structural elucidation, mechanism-of-action studies, toxicity testing, and formulation work. But the comprehensive nature of this assessment, spanning antimicrobial, anti-inflammatory, antidiabetic, and antiproliferative activities alongside full chemical profiling and fermentation optimization, gives the almond fungus PB1 a unusually complete starting dossier. It is exactly the kind of well-characterized lead that natural-products researchers hope will seed the next generation of microbe-derived medicines, and it arrived, fittingly, from a handful of almonds.

Subject of Research: Bioactive secondary metabolites from an almond-derived Penicillium citrinum strain

Article Title: Unveiling the pharmacological potential of Penicillium citrinum PB1 isolated from almonds: a comprehensive bioactivity assessment

Article References: Unveiling the pharmacological potential of Penicillium citrinum PB1 isolated from almonds: a comprehensive bioactivity assessment. (n.d.). https://doi.org/10.1007/s13205-026-05066-6

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05066-6

Keywords: Penicillium citrinum, almonds, secondary metabolites, antimicrobial activity, MIC, anti-inflammatory, antidiabetic, alpha-glucosidase, GC-MS, HPLC, fermentation optimization, natural products

The research, led by Eddie Guillermo Sanchez-Rueda and colleagues at the Laboratory of Biomolecular Engineering and Bionanotechnology of the Institute of Chemistry at the National Autonomous University of Mexico, focused on two well-characterized antimicrobial peptides with very different origins. The first, aurein 1.2, is a short amphipathic peptide originally described from the skin secretions of Australian tree frogs, known for disrupting bacterial membranes. The second, myxinidin, is a peptide derived from a fish pathogen, which has attracted attention for its activity against a broad range of Gram-negative bacteria. Both peptides are small, positively charged, and membrane-active, which makes them attractive drug candidates but also makes them difficult guests in a living production cell.

The team’s central design decision was to genetically fuse each peptide to a triblock polypeptide the authors call CSB, a protein-engineering scaffold that self-assembles into nanoparticles. Rather than letting the antimicrobial peptides float freely in the yeast cell, where their membrane-disrupting activity could poison the host and depress yields, the fusion strategy tethers them to a larger, structured carrier. Once the fusion proteins are produced and purified, the CSB block drives the molecules to organize themselves into discrete protein nanoparticles, effectively immobilizing the peptides within a supramolecular architecture. This kind of self-assembling carrier serves a dual purpose: it shields the producing organism during fermentation, and it creates a nanoparticle format that could later be useful for delivery or formulation of the antimicrobial cargo.

Producing the fusion proteins in Pichia pastoris required careful optimization of the fermentation conditions, and this is where much of the study’s practical value lies. Pichia is a workhorse of industrial biotechnology, prized for its ability to grow to very high cell densities and for a strong, tightly regulated promoter that responds to methanol. The researchers systematically varied the concentrations of glycerol, used as a carbon source for building biomass, and methanol, used to induce expression of the recombinant genes, along with the pH of the culture medium. The outcome of these experiments was strikingly clear: the single most important factor was allowing the yeast to accumulate extensive biomass before the methanol induction was triggered, combined with letting the medium acidify to a permissive pH of approximately 3.

Under those optimized conditions, the gains were dramatic. The aurein 1.2–CSB fusion, abbreviated Aur-CSB, increased in yield by up to 35.3-fold, reaching 35.95 plus or minus 19.05 milligrams per liter of culture. The myxinidin–CSB fusion, Myx-CSB, showed a more modest but still substantial improvement of up to 5.5-fold, reaching 12.96 plus or minus 5.75 milligrams per liter. The difference between the two constructs is itself informative, because it illustrates a familiar reality of recombinant protein production: even two peptides of similar size and function can behave very differently once fused to the same carrier, and yields must be tuned construct by construct rather than assumed from a general protocol.

After purification, the critical question was whether the fusion proteins actually did what the design intended: assemble into nanoparticles. The researchers turned to two complementary biophysical techniques to find out. Atomic force microscopy, which scans a sharp probe across a surface to map its topography with nanometer resolution, and dynamic light scattering, which infers particle size from fluctuations in scattered laser light, both confirmed self-assembly. Interestingly, the three constructs adopted different morphologies. The bare CSB polypeptide formed rod-shaped nanoparticles with an average height of 3.55 plus or minus 0.38 nanometers, while both the Aur-CSB and Myx-CSB fusions formed globular particles, with average heights of 9.79 plus or minus 1.56 nanometers and 9.28 plus or minus 0.99 nanometers respectively. The attached antimicrobial peptides thus appear to influence not just the yield but the geometry of the assembled structures.

With the nanoparticles in hand, the team moved to a preliminary test of biological function, using Escherichia coli as the target organism. Rather than relying on a single assay, they combined fluorescent probes that report on different aspects of bacterial health. A live/dead viability test based on SYTO 9 and propidium iodide staining was used to assess membrane integrity: SYTO 9 stains all cells green, while propidium iodide, which cannot cross intact membranes, only enters and stains red those cells whose membranes have been compromised. Hoechst dye was used to stain bacterial DNA, providing an additional readout. Both the culture supernatants containing the expressed AMP-CSB fusions and the purified nanoparticles displayed preserved antimicrobial activity in these assays, indicating that the peptides had not lost their membrane-disrupting potency by being locked into the nanoparticle format.

The significance of that last point is hard to overstate. One of the recurring fears in fusion-based production of antimicrobial peptides is that burying the active sequence inside a larger protein or a supramolecular structure will neutralize it, forcing researchers to choose between yield and activity. This study suggests the trade-off can be avoided: the CSB scaffold protects the yeast during production, assembles into defined nanoparticles after purification, and still leaves the antimicrobial function intact enough to compromise E. coli membranes. The authors are careful to frame the activity data as preliminary, and fluorescence-based membrane assays are a first screening step rather than a full pharmacological characterization, but the proof of concept is complete across the whole chain from gene to functional nanoparticle.

The broader context makes the work timely. As multidrug-resistant infections continue to spread, the pipeline for new antibiotics remains thin, and antimicrobial peptides are among the few candidate classes moving from academic labs toward clinical and agricultural applications. What has been missing, in many cases, is a manufacturing route that is scalable, economical, and compatible with the biological activity of the product. Yeast fermentation in Pichia pastoris is already used industrially for enzymes, vaccines, and biopharmaceuticals, so demonstrating that AMP-nanoparticle fusions can be produced there, with yields improved by simple and transferable fermentation parameters, lowers a significant barrier. The finding that high pre-induction biomass and acidic culture conditions around pH 3 boost production is the kind of process knowledge that can be directly adopted by other groups working on similar constructs.

There is also a nanotechnology dimension that extends beyond antibiotics. The CSB triblock polypeptide belongs to a growing family of genetically encoded, self-assembling protein building blocks that can form nanoparticles of controlled shape and size without chemical crosslinkers. Fusing functional peptides to such scaffolds turns the nanoparticles into programmable multivalent display platforms, with potential uses in drug delivery, vaccination, biosensing, and materials science. By showing that the identity of the fused peptide changes the assembly morphology, from rods to globules, the Mexican team has added a data point to the emerging design rules for these systems. The study, which was supported by UNAM-PAPIIT funding and carried out within a doctoral program spanning UNAM and the University of Groningen, establishes key parameters for efficient production of self-assembling AMP-based protein nanoparticles in Pichia pastoris and provides a scalable platform for their further development and functional characterization. If subsequent work confirms and extends the antimicrobial findings to other pathogens, the humble yeast tank could become an unexpected factory for the next generation of nanostructured antibiotics.

Subject of Research: Recombinant production of antimicrobial peptide nanoparticles in Pichia pastoris

Article Title: Production of antimicrobial peptides fused to a nanoparticle-forming polypeptide using Pichia pastoris

Article References: Sanchez-Rueda, E. G., Cruz-Garcia, B. B., Hernandez-Cortes, F. O., Trejo-Perez, M. A., Valentinotti-Bonardi, L., Clairin-Savage, A., Ramírez-Carreto, S., & Hernandez-Garcia, A. (2026). Production of antimicrobial peptides fused to a nanoparticle-forming polypeptide using Pichia pastoris. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14033-3

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14033-3

Keywords: antimicrobial peptides, Pichia pastoris, nanoparticles, self-assembly, recombinant protein production, aurein 1.2, myxinidin, antibiotic resistance, biotechnology, fermentation optimization, atomic force microscopy, E. coli